Physician profile
Sara Ramquist
NPI 1245762459
$8,263.96
in general payments reported to CMS, 2019-2025
47 companies · $1,481 in 2025
The $1,481 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $593 · 2020: $320 · 2021: $1,066 · 2022: $1,219 · 2023: $1,365 · 2024: $2,220 · 2025: $1,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,066.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,479.12 | 2021-2025 | |
| Ucb, INC. | $583.36 | 2022-2025 | Briviact, Rystiggo, Fintepla |
| Genentech USA, INC. | $513.08 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Pfizer INC. | $420.04 | 2023-2025 | |
| Biogen, INC. | $409.40 | 2020-2024 | Vumerity, Tysabri |
| Lilly USA, LLC | $326.40 | 2020-2025 | Amyvid, Emgality, Kisunla |
| Eisai INC. | $324.90 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $324.85 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $305.35 | 2021-2025 | Nuplazid |
| Biohaven Pharmaceuticals, INC. | $304.91 | 2021 | |
| Amneal Pharmaceuticals LLC | $291.37 | 2019-2025 | Crexont, Rytary, Lyvispah |
| Alexion Pharmaceuticals, INC. | $282.06 | 2019-2025 | Soliris, Ultomiris |
| Sk Life Science, INC. | $272.14 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $193.46 | 2021-2025 | Austedo Xr, Austedo Xr |
| Mdd US Operations, LLC | $191.00 | 2022-2025 | Gocovri, Gocovri |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Ramquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.